AETHLON MEDIC.NEW DL-001
Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, … Read more
AETHLON MEDIC.NEW DL-001 (EJU) - Net Assets
Latest net assets as of December 2025: €6.71 Million EUR
Based on the latest financial reports, AETHLON MEDIC.NEW DL-001 (EJU) has net assets worth €6.71 Million EUR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€8.06 Million) and total liabilities (€1.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €6.71 Million |
| % of Total Assets | 83.32% |
| Annual Growth Rate | -11.2% |
| 5-Year Change | -44.87% |
| 10-Year Change | N/A |
| Growth Volatility | 46.74 |
AETHLON MEDIC.NEW DL-001 - Net Assets Trend (2020–2025)
This chart illustrates how AETHLON MEDIC.NEW DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AETHLON MEDIC.NEW DL-001 (2020–2025)
The table below shows the annual net assets of AETHLON MEDIC.NEW DL-001 from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €5.12 Million | -11.15% |
| 2024-03-31 | €5.77 Million | -61.72% |
| 2023-03-31 | €15.06 Million | -11.34% |
| 2022-03-31 | €16.99 Million | +82.83% |
| 2021-03-31 | €9.29 Million | +0.18% |
| 2020-03-31 | €9.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AETHLON MEDIC.NEW DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5592843600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €173.08 Million | 3378.11% |
| Total Equity | €5.12 Million | 100.00% |
AETHLON MEDIC.NEW DL-001 Competitors by Market Cap
The table below lists competitors of AETHLON MEDIC.NEW DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OCCID.PETROL CORP
MU:OPC
|
$446.21K |
|
Megaron SA
WAR:MEG
|
$446.45K |
|
BENCHMARK ELECTRS
MU:BMU
|
$446.62K |
|
MONDELEZ INT-A - Dusseldorf Stock Exchang
DU:KTF
|
$446.68K |
|
Binah Capital Group, Inc. Warrants
NASDAQ:BCGWW
|
$445.59K |
|
First Colombia Gold Corp
PINK:FCGD
|
$444.75K |
|
PROPHECY DEFI INC.
F:V8M
|
$444.51K |
|
International Stem Cell Corp
OTCQB:ISCO
|
$444.06K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AETHLON MEDIC.NEW DL-001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,766,332 to 5,123,530, a change of -642,802 (-11.1%).
- Net loss of 13,388,089 reduced equity.
- New share issuances of 3,539,907 increased equity.
- Other factors increased equity by 9,205,380.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.39 Million | -261.31% |
| Share Issuances | €3.54 Million | +69.09% |
| Other Changes | €9.21 Million | +179.67% |
| Total Change | €- | -11.15% |
Book Value vs Market Value Analysis
This analysis compares AETHLON MEDIC.NEW DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.66x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.42x to 1.66x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | €10.05 | €4.24 | x |
| 2021-03-31 | €7.76 | €4.24 | x |
| 2022-03-31 | €11.11 | €4.24 | x |
| 2023-03-31 | €6.55 | €4.24 | x |
| 2024-03-31 | €17.54 | €4.24 | x |
| 2025-03-31 | €2.55 | €4.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AETHLON MEDIC.NEW DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -261.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.44x
- Recent ROE (-261.31%) is below the historical average (-127.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -67.74% | -980.33% | 0.06x | 1.10x | €-7.31 Million |
| 2021 | -83.63% | -1196.58% | 0.06x | 1.13x | €-8.83 Million |
| 2022 | -60.80% | -3540.90% | 0.02x | 1.13x | €-12.13 Million |
| 2023 | -79.86% | -2094.89% | 0.03x | 1.16x | €-13.54 Million |
| 2024 | -211.71% | 0.00% | 0.00x | 1.43x | €-12.78 Million |
| 2025 | -261.31% | 0.00% | 0.00x | 1.44x | €-13.90 Million |
Industry Comparison
This section compares AETHLON MEDIC.NEW DL-001's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $279,466,636
- Average return on equity (ROE) among peers: -73.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AETHLON MEDIC.NEW DL-001 (EJU) | €6.71 Million | -67.74% | 0.20x | $446.12K |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| Scandinavian Real Heart AB (Publ) (7820) | $111.29 Million | -9.42% | 0.06x | $4.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |